Correlation Between Karolinska Development and Oncopeptides

Can any of the company-specific risk be diversified away by investing in both Karolinska Development and Oncopeptides at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karolinska Development and Oncopeptides into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karolinska Development AB and Oncopeptides AB, you can compare the effects of market volatilities on Karolinska Development and Oncopeptides and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karolinska Development with a short position of Oncopeptides. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karolinska Development and Oncopeptides.

Diversification Opportunities for Karolinska Development and Oncopeptides

0.83

Correlation Coefficient

Karolinska Development  Oncopeptides

Very poor diversification

The 3 months correlation between Karolinska and Oncopeptides is 0.83. Overlapping area represents the amount of risk that can be diversified away by holding Karolinska Development AB and Oncopeptides AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncopeptides AB and Karolinska Development is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karolinska Development AB are associated (or correlated) with Oncopeptides. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncopeptides AB has no effect on the direction of Karolinska Development i.e., Karolinska Development and Oncopeptides go up and down completely randomly.

Pair Corralation between Karolinska Development and Oncopeptides

Assuming the 90 days trading horizon Karolinska Development AB is expected to generate 0.81 times more return on investment than Oncopeptides. However, Karolinska Development AB is 1.23 times less risky than Oncopeptides. It trades about -0.08 of its potential returns per unit of risk. Oncopeptides AB is currently generating about -0.14 per unit of risk. If you would invest  123.00  in Karolinska Development AB on September 12, 2024 and sell it today you would lose (21.00) from holding Karolinska Development AB or give up 17.07% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Karolinska Development AB  vs.  Oncopeptides AB

Karolinska Development

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karolinska Development AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Oncopeptides AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Karolinska Development and Oncopeptides

The main advantage of trading using opposite Karolinska Development and Oncopeptides positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karolinska Development position performs unexpectedly, Oncopeptides can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncopeptides will offset losses from the drop in Oncopeptides' long position.

The idea behind Karolinska Development AB and Oncopeptides AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.